Peripheral Arterial Disease Clinical Trial
Official title:
ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease
Leg pain caused by peripheral arterial disease (PAD) can severely impede walking ability. Our preliminary findings indicate that the drug ramipril is much more effective in improving walking ability than current therapies. To be accepted as a new treatment for PAD these findings require validation in a much larger clinical trial.We propose to examine the effects of ramipril therapy for 6 months in a randomized, controlled trial of patients with PAD. If positive, this study will identify ramipril as a potential new therapy for PAD.
This proposal extends our novel finding that the angiotensin-converting enzyme (ACE)
inhibitor, ramipril markedly improves walking ability in patients with peripheral arterial
disease (PAD), by conducting a larger clinical trial including a broader cross-section of
PAD patients.
Hypothesis:
That ramipril therapy for 24 weeks will result in clinically significant increases in both
pain-free and maximum walking time and improve quality of life in patients with PAD.
Background Synopsis:
Peripheral arterial disease is a common disorder, with 12% of adults over 50 having an
ankle-brachial index (ABI) diagnostic of PAD (<0.9). Approximately one third of these
patients experience intermittent claudication during walking, limiting the ability of these
older individuals to participate in normal activities. The aim of PAD treatment is to
improve walking distance and quality of life in those with intermittent claudication, and to
decrease long term cardiovascular morbidity and mortality. However, the range of medical
treatments to improve walking distance in these patients is limited. Our pilot study
demonstrates that treatment of PAD patients, with infra-inguinal disease and without
diabetes with ramipril for 24 weeks, markedly improves waking ability. Relative to placebo,
ramipril increased mean treadmill-assessed pain-free waking time by 227s (160%, p<0.001) and
mean maximum walking time by 451s (240%, p<0.001). Assuming a constant speed of 0.89 m/s
(3.2 km/hr), this corresponds to a clinically significant increase in walking distance of
401m (95% CI 330m to 480m) which would impact appreciably on daily functional capacity. The
magnitude of this effect is significantly greater than that reported for conventional
medical therapies and provides worthwhile clinical benefit.
Research Plan Synopsis:
The dramatic findings of our pilot study clearly warrant verification in a larger clinical
trial including diabetic patients and those with aorto-iliac disease as well as
infra-inguinal disease. The current proposal is to expand our pilot study into a large trial
with broad inclusion criteria. We propose to include patients with diabetes mellitus not
currently medicated with ACE inhibitors. 264 PAD patients will be randomised to either
ramipril (10mg once daily) or matching placebo for 24 weeks in a randomised, double-blind
placebo controlled trial. All patients will undergo a treadmill exercise test to determine
pain free and maximum walking times, ABI measurements and Duplex scanning to determine
stenosis severity, both at baseline and following 6 months of ramipril therapy. Functional
capacity in a daily life setting, will be assessed using standardised questionnaires
(Walking Impairment Questionnaire and Quality of Life Questionnaire).
Outcomes and Significance:
If positive this trial will validate our pilot findings that the ACE inhibitor ramipril is
an efficacious new therapy for the treatment of patients with claudication resulting from
PAD. Given the escalating prevalence of PAD, this work has the potential for widespread
impact.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |